Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation [PDF]
Haematologica, 2014 This is the first prospective study of deferasirox in adult allogeneic hematopoietic stem cell transplant recipients with transfusional iron overload in hematologic malignancies.
Carlos Vallejo +13 more
doaj +4 more sources
Application of Fuzzy AHP for Medication Decision Making in Iron-Chelating Medications for Thalassemia. [PDF]
Pharmacy (Basel)Iron overload is a significant concern for patients with thalassemia and often necessitates the use of iron-chelating agents to mitigate the associated complications.
Barzegari S +3 more
europepmc +2 more sources
Deferasirox improved iron homeostasis and hematopoiesis in ovariectomized rats with iron accumulation. [PDF]
Sci RepMenopause is a natural biological aging process characterized by the loss of ovarian follicular function and decrease estrogen levels. These hormonal fluctuations are associated with increased iron levels, which ultimately lead to iron accumulation. This
Honari N +4 more
europepmc +2 more sources
Fluvastatin suppresses hemin-induced cell death, reactive oxygen species generation, and elevated labile iron pool. [PDF]
Hematol Transfus Cell TherBackground: In transfusion-related iron overload, macrophage/reticuloendothelial cells are the first site of haem-derived iron accumulation. The prevention of haem-induced cytotoxicity in macrophages may represent a target for iron overload treatment ...
Imoto S +6 more
europepmc +2 more sources
Molecules, 2021 Deferasirox is an orally active, lipophilic iron chelating drug used on thousands of patients worldwide for the treatment of transfusional iron overload. The essential transition metals iron and copper are the primary catalysts of reactive oxygen species
Viktor A. Timoshnikov +4 more
doaj +1 more source
Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome [PDF]
Anais Brasileiros de Dermatologia, 2017 Deferasirox is an iron chelator agent used in the treatment of diseases with iron overload, such as thalassemia and myelodysplastic syndrome. Although the majority of adverse reactions of deferasirox involve gastrointestinal symptoms and increase in ...
Asude Kara Polat +3 more
doaj +2 more sources
Development and Validation of a Method for Determining Deferasirox in Human Blood Plasma by HPLC-UV
Разработка и регистрация лекарственных средств, 2022 Introduction. Deferasirox is one of the most well-known complexing drugs chelators and is successfully used in chelating therapy for the treatment of excess iron in the human body. Deferasirox is also included in the list of vital and essential medicines,
P. A. Karpova +7 more
doaj +1 more source
Efficacy and Side Effects of Deferasirox and Deferiprone for Thalasemia Major in Children [PDF]
Pharmacology and Clinical Pharmacy Research, 2016 Thalassemia major (TM) is an inherited disease caused by defective or absent of hemoglobin chain synthesis. Regular chelation therapy is necessary to reduce excess iron in several organs of TM patients.
Asti Y. Rindarwati +2 more
doaj +1 more source
Haematologica, 2023 CALYPSO (clinicaltrials gov. Identifier: NCT02435212), a randomized, open-label, multicenter, phase II study evaluated the compliance, clinical benefits, and safety of deferasirox granules and dispersible tablets (DT) in pediatric patients with iron ...
Ali T. Taher +8 more
doaj +1 more source
Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy [PDF]
, 2012 The effect of deferasirox dosing tailored for iron burden and iron loading based on liver iron concentration (LIC) was assessed over 1 year in less versus more heavily iron-overloaded patients in a substudy of the Evaluation of Patients' Iron Chelation ...
A. El-Beshlawy +9 more
core +1 more source